SuperworthMaravai Lifesciences profit margin MRVI
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- −37.1%
- Operating margin, 12 months
- −56.1%
- Net margin on a year earlier
- +50.5 pts
- Peer median
- 10.9%
Over the twelve months to Jun 30, 2026, Maravai Lifesciences kept −37.1% of its revenue as net profit, with an operating margin of −56.1% and a gross margin of 34.9%.
Five years earlier its net margin was 24.7%.
The median for 10 large drugmakers of a similar size is 10.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −70.4% | n/a | 18.3% |
| FY2024 | −55.9% | −90.9% | 41.8% |
| FY2023 | −41.2% | −11.0% | 48.5% |
| FY2022 | 24.9% | 65.0% | 80.9% |
| FY2021 | 22.8% | 69.4% | 82.4% |
| FY2020 | 31.3% | 42.2% | 72.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −37.1% | +50.5 pts | −56.1% | |
| Q1 FY26 | −51.1% | +16.2 pts | −82.2% | |
| Q4 FY25 | −70.4% | −14.5 pts | n/a | |
| Q3 FY25 | −62.9% | +18.4 pts | n/a | |
| Q2 FY25 | −87.6% | −38.7 pts | n/a | |
| Q1 FY25 | −67.3% | −19.5 pts | n/a | |
| Q4 FY24 | −55.9% | −14.7 pts | −90.9% | |
| Q3 FY24 | −81.3% | −87.1 pts | −74.1% | |
| Q2 FY24 | −48.9% | −62.8 pts | −20.0% | |
| Q1 FY24 | −47.8% | −69.2 pts | −19.4% | |
| Q4 FY23 | −41.2% | −66.1 pts | −11.0% | |
| Q3 FY23 | 5.9% | −20.4 pts | 20.2% |
Against its peers
Companies in Drug Manufacturers - General nearest Maravai Lifesciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| MRVIMaravai Lifesciences | −37.1% |
| HRMYHarmony Biosciences | 18.9% |
| ANIPANI Pharmaceuticals | 11.1% |
| PBHPrestige Consumer Healthcare | 15.6% |
| PAHCPhibro Animal Health | 6.6% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| NRIXNurix Therapeutics | 42.0% |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OGNOrganon | 3.4% |
| Peer median | 10.9% |
Where Maravai Lifesciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Maravai Lifesciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.